BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31818250)

  • 1. NK cell predicts the severity of acute graft-versus-host disease in patients after allogeneic stem cell transplantation using antithymocyte globulin (ATG) in pretreatment scheme.
    Zhang P; Yang S; Zou Y; Yan X; Wu H; Zhou M; Sun YC; Zhang Y; Zhu H; Xu K; Wang Y; Sheng LX; Mu Q; Sun L; Ouyang G
    BMC Immunol; 2019 Dec; 20(1):46. PubMed ID: 31818250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
    Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
    J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.
    Salem G; Ruppert AS; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos L; Klisovic R; Vasu S; Blum W; Devine SM; Jaglowski S; Efebera YA
    Leuk Lymphoma; 2015 Apr; 56(4):1058-65. PubMed ID: 25166008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia.
    Chen X; Wei J; Huang Y; He Y; Yang D; Zhang R; Jiang E; Ma Q; Zhai W; Yao J; Zhang G; Feng S; Han M
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):86-90. PubMed ID: 29032265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine Release Syndrome during Antithymocyte Globulin/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria.
    Knaus HA; Rottner T; Baumann CK; Cserna J; Mitterbauer M; Schulenburg A; Rabitsch W; Wohlfarth P
    Transplant Cell Ther; 2022 May; 28(5):260.e1-260.e9. PubMed ID: 35217212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.
    Wakamatsu M; Terakura S; Ohashi K; Fukuda T; Ozawa Y; Kanamori H; Sawa M; Uchida N; Ota S; Matsushita A; Kanda Y; Nakamae H; Ichinohe T; Kato K; Murata M; Atsuta Y; Teshima T;
    Blood Adv; 2019 Jan; 3(2):105-115. PubMed ID: 30626574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.
    Yuan J; Pei R; Su W; Cao J; Lu Y
    Oncotarget; 2017 Feb; 8(7):10871-10882. PubMed ID: 28107198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of low-dose anti-thymocyte globulin on immune reconstitution after allogeneic hematopoietic cell transplantation.
    Ito A; Kitano S; Tajima K; Kim Y; Tanaka T; Inamoto Y; Kim SW; Yamamoto N; Fukuda T; Okamoto S
    Int J Hematol; 2020 Jan; 111(1):120-130. PubMed ID: 31641956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation.
    Binkert L; Medinger M; Halter JP; Heim D; Gerull S; Holbro A; Lengerke C; Weisser M; Passweg JR
    Bone Marrow Transplant; 2015 Oct; 50(10):1331-6. PubMed ID: 26121111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antithymocyte globulin for GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation].
    Shiratori S
    Rinsho Ketsueki; 2021; 62(8):1265-1274. PubMed ID: 34497215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.